Physician profile
James Varnell
NPI 1053389734
$732.06
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $508 · 2020: $142 · 2021: $82.28.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $201.89 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $153.62 | 2019 | |
| Pfizer INC. | $74.33 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $69.66 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $59.49 | 2019-2021 | |
| Braemar Manufacturing, LLC | $57.50 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $28.56 | 2020 | |
| Boston Scientific Corporation | $21.44 | 2020 | |
| Philips North America LLC | $17.66 | 2020 | |
| Esperion Therapeutics, INC. | $16.68 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $15.87 | 2019 | |
| Merck Sharp & Dohme LLC | $15.36 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Varnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.